



Program Announcement for the Defense Health Agency

Peer Reviewed Cancer Research Program Impact Award

Funding Opportunity Number: HT942526PRCRPIPA

Pre-Application Due: June 26, 2026

Application Due: October 5, 2026

This program announcement must be read in conjunction with the General Application Instructions, version [CD26_01](#).

Content

Before You Begin	3
<hr/>	
① Basic Information	4
Summarizes the <u>funding opportunity</u> , <u>funding details</u> , <u>submission deadlines and review dates</u>	
② Eligibility	5
Details eligibility factors for the <u>applicant organization</u> and <u>Principal Investigator</u>	
③ Program Description	6
Describes the <u>program mission</u> and <u>intent of the Impact Award</u> ; provides <u>key award information</u> and <u>considerations</u> ; and outlines <u>funding details</u>	
④ Application Contents	17
Presents the two-step <u>application process</u> and instructions for preparing a <u>pre-application</u> and <u>full application</u>	
⑤ Submission Requirements	28
Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	
⑥ Application Review Information	31
Outlines the processes for application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also, details the review criteria for <u>pre-application screening</u> and both tiers of the CDMRP application review process – <u>Peer Review</u> and <u>Programmatic Review</u>	
⑦ Federal Award Notices	37
Outlines what a successful applicant can expect <u>if recommended for funding</u>	
⑧ Post-Award Requirements	38
References <u>policy requirements</u> for funded research; outlines <u>reporting requirements</u> and restrictions related to <u>Principal Investigator changes</u> and <u>institutional award transfers</u>	
⑨ Other Information	40
Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	
Appendix 1	43
Includes a checklist for all full application components to facilitate application submission	
Appendix 2	45
Acronym List	

Before You Begin

- **Active [SAM.gov](#), [eBRAP.org](#) and [Grants.gov](#) registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process [FAQ](#), a [Guide for Intragovernmental & Intramural Applicants](#) and a [CDMRP Video Series](#) detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

*Questions regarding
funding opportunity submission
requirements,
as well as technical assistance
related to pre-application or
intramural application submission.*

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

*Questions regarding
Grants.gov registration
and Workspace.*

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click  to be taken to additional guidance and instructions within the General Application Instructions (GAI).

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#) | [Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS).

Distinctive Features:

- Applications must include preliminary data to support feasibility of the study.
- Projects must have strong potential to result in a near-term impact in cancer.
- The funding mechanism allows **clinical trials**.
- **This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI.** Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI's application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly \$45.0M to fund approximately 30 Impact Award applications with total cost caps of \$1.5M per award and \$28.0M to fund approximately 14 Impact Award-Partnering PI Option applications with total cost caps of \$2.0M. The maximum period of performance is 3 years. It is anticipated that awards made from this fiscal year 2026 (FY26) funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), June 26, 2026
- **Invitation to Submit an Application:** August 10, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, October 5, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, October 8, 2026
- **Peer Review:** December 2026
- **Programmatic Review:** February 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PRCRPIPA

Assistance Listing Number: 12.420

Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

[Extramural](#) and [intramural U.S. Department of Defense \(DOW\)](#) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

2.1.2. Principal Investigator

Independent investigators at all career levels are eligible to be named as the PI or partnering PI on the application.

Independent Investigators at all career levels affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional [recipient qualification requirements](#).

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Peer Reviewed Cancer Research Program (PRCRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PRCRP in 2009 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the PRCRP from FY09 through FY25 totaled \$1.17 billion. The FY26 appropriation is \$165 million (M).

Congressional language stipulates the FY26 PRCRP must be relevant to Service Members, and address at least one of the congressionally directed FY26 PRCRP Topic Areas listed below.

- Bladder cancer
- Blood cancers
- Brain cancer
- Colorectal cancer
- Endometrial cancer
- Esophageal cancer
- Germ cell cancers
- Glioblastoma
- Liver cancer
- Lymphoma
- Mesothelioma
- Metastatic cancers
- Myeloma
- Neuroblastoma
- Neuroendocrine Tumors
- Pediatric, adolescent, and young adult cancers¹
- Pediatric brain tumors
- Sarcoma
- Stomach cancer
- Thyroid cancer

Research proposed to the PRCRP must not address research in melanoma, or cancers originating in the breast, kidney, lung, pancreas, prostate or ovary. In addition, FY26 PRCRP funds must not be used to study rare cancers except FY26 PRCRP Topic Area cancer types that are rare by definition.

FY26 PRCRP Portfolios and Strategic Goals

To meet the intent of the funding opportunity, ***all applications for FY26 PRCRP funding must specifically address one of the FY26 PRCRP Topic Areas as directed by the U.S. Congress and have direct relevance to military health.*** Additionally, the PRCRP implements a portfolio-driven approach by grouping related topic areas with strategic goals as a framework within which to address critical gaps in cancer research and patient care. ***All applications must address one of the FY26 PRCRP strategic goals as it relates to the portfolio-assigned FY26 PRCRP Topic Area. Some topic areas are present in more than one portfolio. Applications must align to the strategic goal of the portfolio in which a topic area is included.*** If the proposed research does not specifically address one FY26 PRCRP Topic Area and one FY26 PRCRP strategic goal from a single portfolio, then the government reserves the right to administratively withdraw the application. The government reserves the right to reassign

¹ The definition of adolescents and young adults is derived from the National Cancer Institute (<https://www.cancer.gov/types/aya>). Research should be targeted toward pediatric (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

Section Shortcuts

[Basic Information](#) |
 [Eligibility](#) |
 [Program Description](#) |
 [Application Contents and Format](#) |
 [Submission Requirements](#) |
 [Application Review Information](#) |
 [Federal Award Notices](#) |
 [Post-Award Requirements](#) |
 [Other Information](#)

the application's topic area if submitted to an incorrect topic area. The table below lists the FY26 PRCRP Topic Areas and strategic goals in each PRCRP portfolio category.

Portfolio: Blood Cancers	
<i>All applications under this portfolio must address one topic area and one strategic goal listed below.</i>	
Topic Areas: Blood, Lymphoma, Myeloma	
Knowledge Areas:	Strategic Goals:
Prevention and Etiology	<ul style="list-style-type: none"> • Improve risk assessment of precancerous conditions • Develop early intervention strategies to prevent initiation and/or progression • Investigate autoimmune disorders as risk factors for lymphoma to inform surveillance strategies • Understand the role of cancer stem cells and the tumor microenvironment in the development of blood cancers
Diagnosis and Prognosis	<ul style="list-style-type: none"> • Improve methods for early detection, prognostic evaluation and/or therapeutic stratification • Develop more cost-effective molecular diagnostics • Identify biomarkers to predict progression from indolent disease • Identify unique prognostic factors in pediatric, adolescent and young adult malignancies
Treatment	<ul style="list-style-type: none"> • Develop new, less toxic therapies • Develop methods to predict therapeutic vulnerabilities • Develop therapies that don't require hospitalization • Develop therapies employing gene editing technologies and cell therapies • Identify contribution of immune niche to initial treatment response and relapse • Develop therapeutic options for patients who fail last line therapies
Survivorship	<ul style="list-style-type: none"> • Develop strategies to minimize and mitigate treatment toxicities • Improve quality of life for survivors and/or caregivers • Identify long-term effects of gene editing and cell therapies and develop risk-based standards for surveillance of treated patients • Improve understanding of the effects of long-term immunosuppression
Epidemiology	<ul style="list-style-type: none"> • Design population-based studies to identify and characterize risk factors related to malignancy

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
 Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Portfolio: Gastroenterological Cancers	
<i>All applications under this portfolio must address one topic area and one strategic goal listed below.</i>	
Topic Areas: Colorectal cancer, Esophageal cancer, Liver cancer, Stomach cancer	
Knowledge Areas:	Strategic Goals:
Prevention and Etiology	<ul style="list-style-type: none"> • Identify modifiable and non-modifiable risk factors to inform prevention strategies • Identify factors driving the increasing rates of early-age onset disease • Identify environmental and genetic factors associated with an increased cancer risk • Identify key drivers of conversion from precancerous lesions into cancer • Explore the interplay between the microbiome and infectious agents in cancer initiation and progression • Conduct integrative studies that analyze stool, blood and the microbiome as they impact disease onset and patient outcomes
Diagnosis and Prognosis	<ul style="list-style-type: none"> • Improve methods for early detection, prognostic evaluation and/or therapeutic stratification • Develop cost-effective and minimally invasive tools for early detection • Develop preclinical models to study disease development
Treatment	<ul style="list-style-type: none"> • Develop new, less toxic therapies • Develop effective treatments for advanced disease • Develop immunotherapies and novel targeting therapies • Identify combination therapies to improve patient outcomes • Identify predictive biomarkers to determine treatment response • Develop integrated treatment plans to address short and long-term impacts of cancer
Survivorship	<ul style="list-style-type: none"> • Develop strategies to minimize and mitigate treatment toxicities • Improve quality of life for survivors and/or caregivers • Improve post treatment surveillance guidelines • Develop validated tools to measure patient quality of life
Epidemiology	<ul style="list-style-type: none"> • Design population-based studies to identify and characterize risk factors related to malignancy • Implement systems to analyze disease patterns and track patient outcomes to inform best practices • Examine the influence of familial genetics and geographic location on disease onset and treatment outcome

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Portfolio: Neurological Cancers	
<i>All applications under this portfolio must address one topic area and one strategic goal listed below.</i>	
Topic Areas: Brain cancer, Glioblastoma, Pediatric Brain Tumors	
Knowledge Areas:	Strategic Goals:
Prevention and Etiology	<ul style="list-style-type: none"> • Identify biological and environmental exposures, including maternal exposures during pregnancy, that increase risk
Diagnosis and Prognosis	<ul style="list-style-type: none"> • Develop early detection methods that avoid diagnostic uncertainties • Develop effective monitoring for recurrence/refractory disease • Develop less invasive diagnostic procedures
Treatment	<ul style="list-style-type: none"> • Develop new, less toxic therapies • Prevent or overcome treatment resistance • Develop personalized oncological care and synergistic multi-modal therapies • Identify protective therapies to be used in conjunction with toxic therapies to reduce treatment-related damage • Develop less invasive treatment options • Develop therapies that cross the blood-brain-barrier
Survivorship	<ul style="list-style-type: none"> • Develop strategies to minimize and mitigate treatment toxicities • Improve quality of life for survivors and/or caregivers • Develop effective screening, monitoring, and provision of psychosocial support/care for the patient and family • Develop care for patients as they transition from pediatric to adult survivors
Epidemiology	<ul style="list-style-type: none"> • Analyze and assess the incidence/prevalence of brain tumors over time to identify changes in trends
Technology Development	<ul style="list-style-type: none"> • Advance the development or adoption of technologies in areas including artificial intelligence and machine learning, human microbiota, genomics, nanoparticles and robotics

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
 Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Portfolio: Pediatric Adolescent and Young Adult Cancers (PAYAC)	
<i>All applications under this portfolio must address one topic area and one strategic goal listed below.</i>	
Topic Areas: PAYAC, Germ cell cancers, Neuroblastoma, Sarcoma, Thyroid cancer	
Knowledge Areas:	Strategic Goals:
Prevention and Etiology	<ul style="list-style-type: none"> • Determine the molecular basis of cancer predisposition syndromes • Determine the extent to which development of disease is attributable to genetic versus environmental differences • Increase understanding of epigenetic influences on cancer development and progression • Identify biological and environmental exposures, including maternal exposures during pregnancy, that increase risk • Investigate the role of microbiome composition in cancer risk and outcomes
Diagnosis and Prognosis	<ul style="list-style-type: none"> • Improve methods for early detection, prognostic evaluation and/or therapeutic stratification • Develop noninvasive techniques for monitoring progression and recurrence • Identify biomarkers present in early-stage disease • Develop preclinical models that accurately mimic disease • Improve accurate and rapid diagnosis of sub-types of disease
Treatment	<ul style="list-style-type: none"> • Develop new, less toxic therapies • Develop treatments for relapse/recurrence, metastatic and advanced disease • Increase the number of clinical trials, including ones that may not be curative but may improve the quality of life for terminal patients • Generate evidence-based treatment and surveillance strategies to preserve fertility • Reduce secondary cancers arising from treatment regimen
Survivorship	<ul style="list-style-type: none"> • Develop strategies to minimize and mitigate treatment toxicities • Improve quality of life for survivors and/or caregivers • Develop strategies to improve the full implementation of survivorship guidelines • Develop survivorship guidelines based on current/modern therapeutic agents
Epidemiology	<ul style="list-style-type: none"> • Design population-based studies to identify and characterize risk factors related to malignancy

Section Shortcuts

[Basic Information](#) |
 [Eligibility](#) |
 [Program Description](#) |
 [Application Contents and Format](#) |
 [Submission Requirements](#) |
 [Application Review Information](#) |
 [Federal Award Notices](#) |
 [Post-Award Requirements](#) |
 [Other Information](#)

Portfolio: Solid Tumors	
<i>All applications under this portfolio must address one topic area and one strategic goal listed below.</i>	
Topic Areas: Bladder cancer, Endometrial cancer, Mesothelioma, Sarcoma, Germ cell cancers, Thyroid cancer, Neuroendocrine tumors	
Knowledge Areas:	Strategic Goals:
Prevention and Etiology	<ul style="list-style-type: none"> • Develop methods that mitigate or identify risk • Develop prevention strategies • Explore the mechanistic relationship between novel and known risk factors and oncogenesis • Identify convergent etiologies underlining the development of malignancies
Diagnosis and Prognosis	<ul style="list-style-type: none"> • Improve methods for early detection, prognostic evaluation and/or therapeutic stratification • Investigate the interactions of pre-existing autoimmune disease and cancer
Treatment	<ul style="list-style-type: none"> • Develop new, less toxic therapies • Develop feasible precision medicine approaches • Identify ways to tailor therapeutic strategies to minimize toxicity
Survivorship	<ul style="list-style-type: none"> • Develop strategies to minimize and mitigate treatment toxicities • Improve quality of life for survivors and/or caregivers
Epidemiology	<ul style="list-style-type: none"> • Design population-based studies to identify and characterize risk factors related to malignancy

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Portfolio: Metastatic Disease	
<i>All applications under this portfolio must address one topic area and one strategic goal listed below.</i>	
Topic Area: Metastatic Cancers, limited to PRCRP topic area cancers	
Knowledge Areas:	Strategic Goals:
Prevention and Etiology	<ul style="list-style-type: none"> • Identify biomarkers in primary disease that could predict metastatic potential • Prevent immune evasion by circulating tumor cells • Identify how dormant, disseminated tumor cells (DTCs) persist • Identify drivers that initiate DTCs progression to metastatic colonies • Prevent metastatic colonization by maintaining dormancy of DTCs • Investigate clonal divergence of primary tumor cells between metastatic sites to immunological disease
Diagnosis and Prognosis	<ul style="list-style-type: none"> • Improve early detection of metastasis and dormant residual disease • Develop biomarkers that predict and monitor treatment efficacy
Treatment	<ul style="list-style-type: none"> • Develop new, less toxic therapies • Revert metastatic cells to a dormant state • Identify strategies to prevent or overcome treatment resistance • Investigate abscopal effects of primary disease treatment • Determine optimal sequencing of treatments • Eliminate chemotherapy-induced metastasis
Survivorship	<ul style="list-style-type: none"> • Develop strategies to alleviate treatment toxicities • Improve quality of life for survivors and/or caregivers

Metastatic cancer is cancer that has spread from its original location to another place in the body, representing what are known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process.

Applications submitted under any PRCRP topic area, including the Metastatic Cancers topic area, may not address or include research focused on melanoma or cancers that originate in the breast, kidney, lung, pancreas, prostate, or ovaries, or rare cancers (excluding relevant subtypes of the FY26 PRCRP Topic Areas) as part of the research study; such applications will be administratively withdrawn.

FY26 PRCRP Military Health Focus Areas

It is central to the Vision and Mission of the PRCRP that applications are related to military health and mission readiness, and investigators must demonstrate how the proposed research will decrease the burden of cancer on Service Members, their dependents, Veterans and other military beneficiaries (i.e., Retirees and their Family members).

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

In addition to addressing at least one of the required [FY26 PRCRP Topic Areas](#) and [FY26 Strategic Goals](#), **applications for the FY26 Impact Award must define how the research is relevant to Service Members and their Families by addressing at least one of the FY26 PRCRP Military Health Focus Areas listed below.**

FY26 PRCRP Military Health Focus Areas:

- **Environmental exposure risk factors associated with cancer**
 - Environmental and/or occupational risk factors should be relevant to activities specific to the military, such as assigned duties or deployments that may lead to exposures to potential carcinogens (ionizing radiation, chemicals, infectious agents, etc.). For more information on military-related exposures and risk factors for cancer, applicants should refer to Exposure-Related Health Concerns at <https://www.publichealth.va.gov/exposures/health-concerns.asp> or to the PRCRP website (<https://cdmrp.health.mil/prcrp/default>).
- **Mission Readiness and Gaps in Cancer Research**
 - Gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries and the general public.
 - Gaps in quality of life and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public.

Mission readiness under the FY26 PRCRP Military Health Focus Areas refers to the impact of cancer on the Service Member. Decreasing the impact of cancer on Service Members and/or their Families protects the overall military missions. Some examples of relevant research to decrease the impact on mission readiness may include, but are not limited to:

- Studies on the improvement in survival while minimizing effects that would allow a Service Member to return to full duty;
- Treatments to minimize a cancer patient's (either a Service Member's or their Family member's) time in the hospital, thus maximizing the time the Service Member is on duty;
- Effective ways to minimize cancer relapse for Service Members or their Families; and
- Research into improvements in cancer detection that would lead to earlier diagnosis, thus allowing for improved treatment of the Service Member and early return to duty.

For more information on military health and cancer:

- PRCRP (<https://cdmrp.health.mil/prcrp/default>)
- MHS (<https://www.health.mil>)
- U.S. Department of Veterans Affairs (VA) (<https://www.va.gov/>)

The PRCRP strongly encourages investigators to collaborate, integrate, and/or align their research projects with DOW and/or VA research laboratories and programs (Refer to [GAI Appendix 10](#)).

3.1. Intent of the Impact Award

The FY26 PRCRP Impact Award supports high-impact and translational research that can accelerate promising findings toward clinical applicability. The intent of the Impact Award

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

mechanism is to **fund mature research projects** that specifically focus on critical scientific or clinical cancer issues, which have the potential to make a major near-term impact on at least one of the [FY26 PRCRP Topic Areas](#) and in at least one of the [FY26 PRCRP Strategic Goals](#) as outlined in the FY26 PRCRP portfolio categories.

The Impact Award is not intended for basic research. Applicants performing basic research in innovative, high-risk/high-gain studies should apply to the FY26PRCRP Idea Award (HT942526PRCRPIA).

3.1.1. Key Elements for the IPA

- **Impact:** Research supported by the Impact Award (IPA) will demonstrate the potential to accelerate promising findings and have a major impact in the near term on an area of paramount importance in cancer. The proposed study should demonstrate potential to improve patient outcomes in at least one of the [FY26 PRCRP Topic Areas](#) and in at least one of the [FY26 PRCRP Strategic Goals](#) as outlined in the FY26 PRCRP portfolio categories. Proposed projects may include translational or clinical research, including clinical trials. ***The potential impact of the proposed research must be near-term, and while it fundamentally may include the next step in research, it must be significant and go beyond an incremental advance.*** The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient outcomes.
- **Preliminary Data:** The Impact Award is intended to support transformative investigations that leapfrog the cancer research field forward by utilizing previous research findings. ***Applications must include preliminary data to support feasibility of the study.*** Any unpublished, preliminary data provided should originate from the laboratory of the PI or a member of the research team.
- **Continuity of Research:** The Impact Award is intended to support established projects that have moved beyond the realm of basic research.
- **Data Evaluation:** The proposed research should be rigorously designed to include a statistical plan and data analysis plan. The Impact Award is intended to have near-term relevance to patients; therefore, the statistical plan and data analysis plan should represent how significant the results and/or outcomes may be on patient outcomes.
- **Military Relevance:** Relevance to the health care needs of Service Members, Veterans and their Families is a key feature of this award. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:
 - Explanation of how the project addresses an aspect of the target disease that has direct relevance to the health of Service Members, Veterans and their Families.
 - Description of how the knowledge, information, products or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need.
 - Use of military or Veteran populations, samples or datasets in the proposed research, if appropriate.
 - Collaboration with DOW or VA investigators or consultants. A list of websites that may be useful in identifying additional information about ongoing DOW and VA areas of research interest or potential opportunities for collaboration within the FY26 PRCRP Topic Areas can be found in [Appendix 10](#) of the GAI.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Clinical Trial, if applicable:** The proposed clinical trial should begin no later than 12 months after the award date. Investigational New Drug/Investigational Device Exemption application submission plans must be submitted to the program office within 60 days of the award. The application should demonstrate the documented availability of and access to the drug/compound, device and/or other materials needed, as appropriate, for the proposed duration of the study.
- **Partnering PI Option:** The Impact Award includes an option for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to [Section 5.3, Submission Instructions](#).

3.1.2. Other Important Considerations for the IPA

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the [STROBE](#), [CONSORT](#), [SPIRIT](#) and [ARRIVE 2.0](#) guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the VA and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

[Clinical trials](#) are allowed within this funding opportunity.

For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from [clinical research](#).

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the [recommendations](#) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 PRCRP priorities.

3.2. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

3.3. Funding Details

Period of Performance: The maximum period of performance is **3** years.

Application Submissions with a Single PI:

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **\$1.5M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

Application Submissions with the Partnering PI Option:

Cost Cap: The combined total costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed **\$2.0M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

A separate award will be made to each PI's organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

For Both Options Within this Award Mechanism:

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Costs for one investigator to travel to two scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the PRCRP Impact Award.
- Travel in support of multi-institutional collaborations.

Must not be requested for:

- Costs for travel to scientific/technical meetings beyond the limits stated above.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.



Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.



4.2. Pre-Application Components

The Initiating PI must submit the following pre-application components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the [formatting guidelines](#) listed in the GAI.


- **Preproposal Narrative (two-page limit):**

The Preproposal Narrative should include the following:

- **Research Idea:** State the [FY26 PRCRP Topic Area\(s\)](#) and [FY26 PRCRP Strategic Goal](#) the application will address. Describe the rationale and hypothesis and how these support the study's objectives and specific aims. Demonstrate how the research is based on strong preliminary data.
- **Research Strategy:** Describe the methodology and experimental design and explain how they support the project's goals. If the application proposes a clinical trial, briefly describe the study including the intervention, study population, primary endpoints and phase of the trial. Describe the strategy to initiate the clinical study within the first year of the award. (Refer to the definition of a clinical trial in [Section 3.1.2.](#))
- **Impact:** Describe the **potential near-term impact** of the proposed research on at least one of the [FY26 PRCRP Topic Areas](#).
- **Military Relevance:** Explain how the proposed research will lead to promising outcomes for one or more of the selected [FY26 PRCRP Military Health Focus Area\(s\)](#).
- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application **must be uploaded as individual files** and are limited to the following:
 - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
 - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols used in the Preproposal Narrative.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Key Personnel Biographical Sketches:** *All biographical sketches should be uploaded as a single combined file.* Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished. 

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

Partnering PI Option: The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. The application submission process for the Partnering PI uses an [abbreviated full application package](#).

4.3.1. Full Application Components for the PI or Initiating PI

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

- (a) **SF424 Research & Related Application for Federal Assistance Form (*Grants.gov* submissions only):** 

IMPORTANT: When completing the SF424 R&R, enter the **eBRAP log number** assigned during pre-application submission into **Block 4a – Federal Identifier**.

- (b) **Attachments:**

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the [formatting guidelines](#) in the GAI.


- **Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf”.** 

Describe the proposed project in detail using the outline below. ***Inclusion of preliminary data is required.***

- **Background:** Describe how the proposed project addresses a FY26 PRCRP Topic Area and corresponding FY26 PRCRP Strategic Goal. Briefly state how the project addresses an FY26 PRCRP Military Health Focus Area(s). Applicants must provide additional detail about the Military Health focus area in [Attachment 6](#).
- **Hypothesis or Objective:** State the hypothesis or the objective.
- **Specific Aims:** State the specific aims of the study.
- **Research Strategy:**
 - Describe the proposed study in sufficient detail to evaluate its appropriateness and feasibility to test the hypothesis and reach the final objective.
 - Include preliminary data and reconcile it with objectives of the research proposed. Demonstrate how the research is based on strong preliminary data and/or previous clinical and/or translational research outcomes. The application must include preliminary data such as published or unpublished results from the laboratory and/or clinic of the PI(s) or named collaborators.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Provide a well-developed, well-integrated and detailed research plan that supports the translational feasibility and promise of the approach. The application must outline details regarding translation feasibility for clinical studies in [Attachment 8](#).
 - Describe how the application designs all proposed animal studies to achieve the objectives, including the choice of model and endpoints or outcome measures, if applicable. Application must describe additional details on animal studies in [Attachment 9](#).
 - Demonstrate the availability of tissue, data or human subjects for the collection of samples, if applicable. If the proposed research will use human subjects or anatomical samples, include a plan for the recruitment of subjects or the acquisition of samples and document the experience of the PI(s) and/or key collaborators in recruiting human subjects for similar projects.
 - If the application proposes a clinical trial, briefly describe the study including the intervention, study population, primary endpoints and phase of the trial. Describe the strategy to initiate the clinical study within the first year of the award. (Refer to the definition of a clinical trial in [Section 3.1.2.](#)) The application must outline additional details regarding the Clinical Trial Strategy in [Attachment 8](#).
 - Describe potential problems and potential pitfalls and address alternative approaches.
 - Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the U.S. Food and Drug Administration (FDA), if applicable.
 - Statistical Plan and Data Analysis for all applications must be submitted in [Attachment 10](#).
 - Consult appropriate [guidelines](#) to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** 

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support:** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet [eligibility criteria](#). If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
- **Sex as a Biological Variable Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the [CDMRP Directive on Sex as a Biological Variable in Research](#) for additional information.
- **Inclusion Enrollment Plan (Only required if clinical research is proposed. If clinical trial is proposed, this plan should be under Attachment 8):** Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the [Public Health Service \(PHS\) Inclusion Enrollment Report](#), a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.
- **Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the [CDMRP Directive on Sharing Data and Research Resources](#) for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Use of DOW Resources or VA Resources (if applicable):** If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the General Application Instructions, [Appendix 4](#), for additional considerations.

- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** 

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** State the [FY26 PRCRP Topic Area\(s\)](#) and [FY26 PRCRP Strategic Goal](#) the proposed research will address. Present the ideas and reasoning behind the proposed work, and briefly describe the previous clinical and/or translational research outcomes upon which the study is founded. If applicable, describe the clinical trial to be performed.
- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Clinical Trial:** If applicable describe the clinical trial to be performed.
- **Impact:** Briefly describe how the proposed project will have a near-term impact on a critical scientific or clinical problem in at least one of the [FY26 PRCRP Topic Areas](#).
- **Military Relevance:** Identify the [FY26 PRCRP Military Health Focus Area\(s\)](#) to be studied. Briefly describe how the proposed research is relevant to Service Members, Veterans and other military beneficiaries.

- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** 


The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine***. Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- State the [FY26 PRCRP Topic Area\(s\)](#) and [FY26 PRCRP Strategic Goal](#) to be addressed by the research project.
- Describe the scientific objective and rationale for the proposed project.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- If applicable, describe the clinical trial proposed in the application.
- Describe the near-term impact for patients and ultimate applicability of the research. What is the projected time it may take to achieve a patient-related outcome?
- Describe what types of patients will it help and how will it help them. What are the potential clinical applications, benefits and risks?
- State the [FY26 PRCRP Military Health Focus Area\(s\)](#) the proposed research will address. Describe how the proposed research is relevant to Service Members, Veterans and other military beneficiaries.

- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.**  Refer to eBRAP for the [Suggested SOW Format](#).

For guidance on preparing the SOW, refer to either the [Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work](#) or [Example: Assembling a Generic Statement of Work](#), whichever is most appropriate for the proposed effort.

Partnering PI Option: Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task.

- **Attachment 6: Relevance to Military Health Statement (one-page limit): Upload as “MilHealth.pdf”.** *Evaluation of the Relevance to Military Health Statement will occur during programmatic review by only the FY26 PRCRP Programmatic Panel.*

- State the [FY26 PRCRP Military Health Focus Area\(s\)](#) to be addressed in the study.
- Based on published literature of the impact of cancer on military populations, articulate the relevance of the research proposed and show how it will decrease the burden of cancer on Service Members, their Families and Veterans.
- If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- For the [FY26 PRCRP Topic Area\(s\)](#) the proposed research will address, identify the associated environmental and/or exposure risk factors associated risk factors and the short- and long-term impact on basic health, welfare and/or psychosocial wellness of Service Members, Veterans and other military beneficiaries

or

- Identify how the proposed research will support mission readiness through filling a gap in cancer prevention, early detection/diagnosis, prognosis, treatment, quality of life and/or survivorship that may have a profound impact on the health and well-being of Service Members, their Families, Veterans or other beneficiaries.
 - Articulate how the proposed research will advance the knowledge and understanding of cancer, patient care and/or treatment options in the MHS for the benefit of Service Members, Veterans and other military beneficiaries.
 - Describe the anticipated short-term and/or long-term outcomes of the proposed research and their potential impact on the basic health, welfare and/or psychosocial wellness of Service Members, Veterans and other military beneficiaries.
- **Attachment 7: Impact Statement (one-page limit): Upload as “Impact.pdf”.** *The Impact Statement should be written in plain language for lay persons.*

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- State how the research will accelerate promising findings toward clinical applicability and leverage results to maximize impact. State explicitly how the proposed work addresses a critical problem in at least one of the [FY26 PRCRP Topic Areas](#).
- State the [FY26 PRCRP Strategic Goals](#) the application will address and how the proposed research will make a near-term impact.
- Explain how the application’s specific research goals would fit into the pathway of achieving clinical applicability.
- If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Attachment 8: Clinical Strategy Statement, if applicable (no page limit): Upload as “Clinical.pdf”. If funds for a clinical trial are requested, this attachment is required.**
 - Describe the rationale for the proposed clinical trial. Provide a description of the intervention and the endpoints to be measured. Describe the type of clinical trial to be performed (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.
 - If the proposed clinical trial was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically, identify the portions of the study that would be supported with funds from this award.
 - Provide detailed plans for initiating the clinical study within the first year, including FDA Investigational New Drug/Investigational Device Exemption application submission plans within 60 days of the award, if applicable. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.
 - Indicate the access to the study population, recruitment plans and inclusion/exclusion criteria. Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity using the [Public Health Service \(PHS\) Inclusion Enrollment Report](#), which is a three-page fillable PDF form, that can be downloaded from eBRAP. For phase 3 clinical trials, use the form to describe plans for the valid analysis of group differences on the basis of sex, race and/or ethnicity as appropriate for the scientific goals of the study.
 - If applicable, describe the process for obtaining informed consent from human subjects and provide a draft, in English, of the Informed Consent Form.
- **Attachment 9: Animal Research Plan (three-page limit), if applicable: Upload as “AnimalResPlan.pdf”.**

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at <https://arriveguidelines.org/arrive-guidelines>. The

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:


- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
- Summarize the procedures to be conducted. Describe how the study will be controlled.
- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 10: Statistical Plan and Data Analysis (five-page limit): Upload as “Stats.pdf”. All applicants are required to submit a Statistical Plan and Data Analysis.**
 - Describe the statistical methodology and plan including how it supports the stated hypothesis or objective.
 - If the proposed research uses an existing dataset, describe the dataset and how it supports the aims of the project.
 - State the inclusion and exclusion criteria for the subjects (study variables), with sound rationale for the criteria, if applicable.
 - Describe the power analysis and whether it determined population numbers; if not, justify why the power analysis is not essential to the statistical evaluation.
 - State whether the study will include univariate, bivariate or multivariate analyses.
 - State the variables the main analysis will use; include covariates and how the analysis will account for covariates, if applicable.
 - The application should describe and justify the stratification of data, if applicable.
 - Describe how the study will conform to HIPAA, the 1996 Health Insurance Portability and Accountability Act, if applicable.
 - Explain data capture, verification, disposition, if applicable.
 - Describe plans for evaluating data for reproducibility and adjusting for confounding variables.
 - Describe plans for evaluating large datasets, if applicable. For laboratory projects, describe the organization and maintenance of large datasets, if applicable.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information


- **Attachment 11: Letters Confirming Access to Target Military or VA Patient Population(s) or Resource(s) (e.g., Human Anatomical Substances, Databases), if applicable (one-page limit per letter): Upload as “Access.pdf”.** If the proposed research plan involves access to active-duty military and/or VA patient population(s) or resource(s), include a letter of support, signed by the lowest-ranking person with approval authority, confirming such access. If access cannot be confirmed at the time of application submission, the government reserves the right to withhold or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resource(s). Refer to the General Application Instructions, Appendix 3, for additional considerations.
- **Attachment 12: Post-Award Transition Plan (three-page limit): Upload as “Transition.pdf”.**

Describe/discuss the methods and strategies proposed to move the research products to the next phase of development after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below:

- Details of the funding strategy to transition to the next level of development. Include a description of collaborations and other resources that will be used to provide continuity of development.
 - For knowledge products, a description of collaborations and other resources that will be used to provide continuity of development, including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures and other clinical support tools, scientific journal publications, models, simulations and applications. (A “knowledge product” is a non-materiel product that addresses an identified need, topic area, or capability gap; is based on current evidence and research; aims to transition into medical practice, training or tools or to support materiel solutions [systems to develop, acquire, provide and sustain medical solutions and capabilities]; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)
 - A brief schedule and milestones for transitioning the intervention to the next level of development.
 - Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government’s ability to access such products or technologies in the future.
- **Attachment 13: Partnership Statement, if applicable (two-page limit): Upload as “Partnership.pdf”.**
For Partnering PI Option only, describe how the partners’ combined experience will better address the research question and explain why the work should be done together rather than through separate efforts.
 - **Attachment 14: Representations (*Grants.gov submissions only*): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the [Required Representations](#) document available on eBRAP. 

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Attachment 15: Suggested Intragovernmental/Intramural Budget Form (if applicable):** Upload as “IGBudget.pdf”. If an [intramural DOW organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [Suggested Intragovernmental/Intramural Budget](#) form available on eBRAP. 

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.



Grants.gov



eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI(s), or vice versa, even if they are located within the same organization. Refer to [Section 3.3, Funding Details](#), for detailed budget information.

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *if applicable, Grants.gov submissions only)*

4.3.2. Full Application Components for the Partnering PI (if applicable)

Refer to the equivalent attachment above for details specific to each of the following application components. See [Appendix 1](#) for a checklist of the full application components required for the Partnering PI.

(a) [SF424 Research & Related Application](#) for Federal Assistance Form (*Grants.gov Submissions Only*):

(b) **Attachments:**

- [Attachment 5: Statement of Work \(three-page limit\):](#) Upload as “SOW.pdf”. Each PI must submit an identical copy of a jointly created SOW.
- [Attachment 14: Representations \(Grants.gov submissions only\):](#) Upload as “RequiredReps.pdf”.
- [Attachment 15: Suggested Intragovernmental/Intramural Budget Form:](#) Upload as “IGBudget.pdf”.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

(c) Additional Application Materials:

The following are additional application materials for application submission. Follow the instructions specific to the submission portal found within the GAI.



Grants.gov



eBRAP.org

i. Research & Related Personal Data

ii. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

iii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI(s) should not include budget information for the Initiating PI, or vice versa, even if they are located within the same organization. Refer to [Section 3.3, Funding Details](#), for detailed budget information.

iv. Project/Performance Site Location(s)

v. Research & Related Subaward Budget Attachment(s) (if applicable, Grants.gov submissions only)

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, [DoD Instructions 3200.12](#) will be requested.



The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PRCRPIPA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. i

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.


Application Submission Workflow



Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI or Initiating PI through [eBRAP](#), including the submission of contact information for the Partnering PI if selecting the Partnering PI Option. 

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the [eBRAP Help Desk](#) if any changes need to be made.

When starting the pre-application, applicants will be asked to select the following:

- Select the FY26 PRCRP portfolio the proposed research will address.
- Select the primary FY26 PRCRP Topic Area the proposed research will address.
- Select the FY26 portfolio classification and strategic goal to be studied.
- When applicable, the applicant should select a secondary FY26 PRCRP Topic Area. The secondary topic area may be any topic regardless of selected portfolio. Examples include, (not all-inclusive):
 - Applications addressing more than one cancer type should select the two most applicable.
 - Applications addressing a topic area that is the subtype of another topic area (e.g., Lymphoma and Blood Cancers) should select both.
 - Applications addressing a cancer type in PAYAC populations, should select both the cancer type and the PAYAC topic area.
 - Applications addressing metastatic disease in a cancer type should select both the metastatic disease and cancer type category.
- Select the FY26 PRCRP Military Health Focus Area the proposed research will address.

Partnering PI Option: After the Initiating PI confirms submission of the pre-application, the Partnering PI will be notified of the pre-application submission via an email from eBRAP. ***The Partnering PI must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.*** If not previously registered, the Partnering PI must register in eBRAP.

Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI. Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.
- The Partnering PI will not be able to view and modify their full application during the verification period in eBRAP.


When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
 Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information


Application Includes:	Select Mechanism Option:
No Clinical Trial, No Partnering PI	No Option
Clinical Trial, No Partnering PI	Clinical Trial Option
No Clinical Trial, Partnering PI	Partnering PI Option
Clinical Trial, Partnering PI	Clinical Trial Option – Partnering PI Option

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. 

eBRAP Submissions: Only [intramural DOW organizations](#) may submit full applications through eBRAP. 

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. 
The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the [application verification period](#) ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in [Section 1, Basic Information](#).

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's Directive on Research Duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.



Members of the FY26 PRCRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the [FY26 PRCRP Programmatic Panel members](#) can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the PRCRP, pre-applications will be screened based on the following criteria:

- Whether the proposed project addresses at least one of the [FY26 PRCRP Topic Areas](#) and at least one corresponding [FY26 PRCRP Strategic Goal](#), and to what degree the research will lead to a breakthrough or make an impact.
- How well the rationale, hypothesis, proposed methodology and experimental design support the study's objectives and specific aims.
- Whether the proposed research will have a near-term impact on a critical scientific or clinical problem.
- If a clinical trial is proposed, whether the proposed intervention, population and end points are appropriate.
- To what degree the proposed research may lead to promising outcomes for one or more of the selected [FY26 PRCRP Military Health Focus Areas](#).

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Research Strategy and Feasibility**

- How well the application develops and supports the completion of the proposed aims through the hypothesis, specific aims, scientific rationale, experimental design, methods, data collection procedures and analyses.
- How well the applicant designed the proposed studies with human subjects, human biological samples or data sets to achieve reproducible and rigorous results and whether they provide evidence of availability of and access to, the necessary study populations and/or resources, if applicable.
- If applicable, whether the application includes a feasible plan for the recruitment of human subjects or the acquisition of samples and provides evidence of availability of, and access to, the necessary study populations and/or resources.
- Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single sex study is sufficiently strong.
- To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.
- How well the application acknowledges potential problems and addresses potential pitfalls and alternative methods and approaches.
- If applicable, how well the application describes how data will be reported and how it will fulfill a regulatory documentation for the FDA.
- If animal research is proposed, how well the animal study (or studies) is designed to achieve the objectives, including the choice of model and endpoints/outcome measures to be used.
- If applicable, whether the application describes the strategy for the inclusion of women and minorities that is appropriate for the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group and an accompanying rationale for the selection of subjects. If women and minorities are excluded, to what extent the application provided a justification.

- **Impact**

- Whether the application explicitly states how the proposed work addresses at least one of the [FY26 PRCRP Topic Areas](#) and a corresponding [FY26 PRCRP Strategic Goal](#) and describes how the study will make an impact on the selected goal.
- If successful, to what degree the research may have a near-term impact on scientific research or patient outcomes.
- Whether the application demonstrated a pathway to accelerate promising findings toward clinical applicability to have maximize impact.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- **Clinical Trial Strategy (applicable for applications proposing funding for a clinical trial)**
 - How well the rationale for the proposed clinical trial is supported.
 - How well the clinical trial portion of the application is designed with appropriate study variables, controls, recruitment goals and endpoints.
 - Whether the process for obtaining Informed Consent and the Informed Consent Document are adequately disclosing information, including study risks.
 - Whether sufficient evidence is provided to support initiation of the clinical study within the first year.
 - **(If applicable)** Whether plans for data reporting are sufficient for the proposed clinical trial, and whether the data will support a regulatory filing with the FDA.
- **Statistical Plan and Data Analysis**
 - To what extent the statistical methodology and plan supports the stated hypothesis or objective.
 - How well the described dataset supports the aims of the project.
 - To what extent the application evaluated the data for reproducibility and adjusted for confounding variables.
 - Whether the application states if the analyses will be univariate, bivariate or multivariate.
 - How well the application describes variable and identifies any covariates, if applicable. How well the application accounts for covariates and justifies the adjustment.
 - If applicable, how well the application describes and justifies the stratification of data.
 - If applicable, how well the application explains the data capture, verification and disposition.
 - Whether the application describes plans for the valid analysis of group differences on the basis of sex, race and/or ethnicity that are appropriate for the scientific goals of the study.
 - If applicable for laboratory projects, to what extent the application describes and justifies the evaluations, storage of samples and organization and maintenance of large datasets.
 - If applicable, whether the inclusion and exclusion criteria for the subjects are sound. How well the application describes the power analysis and whether it determined population numbers. If applicable, how well the application justified why a power analysis is not essential to the statistical evaluation.
- **Post-Award Transition Plan**
 - Whether the application describes the anticipated research outcomes (e.g., knowledge products, clinical products for development).
 - How well the application demonstrates methods (e.g., funding opportunities, collaborations and intellectual property rights) to move the anticipated research outcomes to the next phase of development or clinical application after successful completion of the project.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- To what degree the application offers a well laid-out strategy to transition to the next level of investigation, development and/or commercialization.
- **Personnel**
 - How appropriate the levels of effort are for successful conduct of the proposed work.
 - How appropriate the PI and research team's background and expertise are with regard to their ability to accomplish the proposed work.

For applications submitted under the **Partnering PI Option**:

- **Partnership**
 - How well the skills and perspectives of the Initiating and Partnering PIs complement each other, bring different strengths to the project and are critical for the research strategy and completion of the SOW.
 - How well the application demonstrates that the combined research/clinical background and experience of both investigators will enhance the application's impact on patient outcomes.
 - How well the application reflects the requirement that the partners have equal intellectual input into the design of the project.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Budget**
 - Whether the budget is appropriate for the proposed research.
- **Environment**
 - To what extent the scientific environment is appropriate for the proposed research project, to include the quality and level of institutional support and the availability of and accessibility to facilities and resources.
- **Application Presentation**
 - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PRCRP, as evidenced by the following:
 - Adherence to the intent of the funding opportunity
 - Relative impact
 - Program portfolio composition
 - Programmatic relevance to the [FY26 PRCRP Military Health Focus Areas](#).

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- Programmatic relevance to the [FY26 PRCRP Strategic Goals](#) as outlined in the FY26 PRCRP portfolio categories.

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, Initiating PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in [Section 1, Basic Information about the Funding Opportunity](#). No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section 6.2.3, Programmatic Review](#).*** Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information


7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PRCRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable [database](#).

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official. 

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

8. Post-Award Requirements


8.1. Administrative and National Policy Requirements


Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding [administrative requirements](#) and [national policy requirements](#).

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [DHACA Research Terms and Conditions](#) for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219. Additionally, the CDMRP requires all funded clinical trials to register and submit study results on [ClinicalTrials.gov](#). 

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), Institutional Review Board (IRB) or Ethics Committee (EC) review. 

8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An [Award Expiration Transition Plan](#), using the template available on eBRAP, must be submitted with the final progress report.

Inclusion Enrollment Reporting: ***(only required for [clinical research studies and clinical trials](#))***: Enrollment reporting on the basis of sex, race and/or ethnicity using the PHS Inclusion Enrollment Report will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.


Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable [Representations](#).

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met. 

The organizational transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of pre-applications or full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- Submission of an application for which a letter of invitation was not issued.
- An application proposing a clinical trial where [Attachment 8](#), Clinical Strategy Statement, is missing.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 PRCRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The federal government recipient organization (including an intramural DOW organization):
(a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The invited application proposes a different research project than that described in the pre-application.
- The PI does not meet the [eligibility criteria](#).
- The pre-application or application does not address at least one of the [FY26 PRCRP Topic Areas](#).
- The pre-application or application does not address at least one of the [FY26 PRCRP Military Health Focus Areas](#).
- The pre-application or application does not address at least one of the [FY26 PRCRP Strategic Goals](#) as outlined in the FY26 PRCRP portfolio categories.
- The application addresses FY26 strategic goal from a portfolio that does not include the selected FY26 topic area.
- The pre-application or application does not adhere to congressional language and includes a cancer that originates in the breast, kidney, lung, pancreas, prostate, or ovary, or rare cancers (excluding relevant subtypes of the FY26 PRCRP Topic Areas), or melanoma as part of the research study.
- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.
- Failure to submit statistical plan and data analysis.
- An investigator may be named as a PI on a single application to this program announcement. If an investigator is named multiple times as a PI, only the first application received will be accepted; additional applications will be administratively withdrawn.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

9.2.5. Other Funding Opportunities

The PRCRP is committed to leveraging efforts with other funding organizations to accelerate progress in [issue] research. At the time of funding notifications, the PRCRP may inform highly rated, unfunded applicants about opportunities to provide their PRCRP applications and peer review summary statements to non-governmental and other governmental funders, who will determine the specific criteria for funding consideration.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
SF424 Research & Related Application for Federal Assistance (<i>Grants.gov submissions only</i>)	<input type="checkbox"/>	<input type="checkbox"/>
Summary (Tab 1) and Application Contacts (Tab 2) (<i>eBRAP submissions only</i>)	<input type="checkbox"/>	<input type="checkbox"/>
Attachments		
Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>	
Supporting Documentation – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>	
Technical Abstract – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>	
Lay Abstract – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>	
Statement of Work – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Relevance to Military Health Statement – Attachment 6, Upload as “MilHealth.pdf”	<input type="checkbox"/>	
Impact Statement – Attachment 7, upload as “Impact.pdf”	<input type="checkbox"/>	
Clinical Strategy Statement (<i>if applicable</i>) – Attachment 8, upload as “Clinical.pdf”	<input type="checkbox"/>	
Animal Research Plan (<i>if applicable</i>) – Attachment 9, upload as “AnimalResPlan.pdf”	<input type="checkbox"/>	
Statistical Plan and Data Analysis – Attachment 10, upload as “Stats.pdf”	<input type="checkbox"/>	
Letters Confirming Access to Target Military or VA Patient Population(s) or Resource(s) (<i>if applicable</i>) – Attachment 11, upload as “Access.pdf”	<input type="checkbox"/>	
Post-Award Transition Plan – Attachment 12, upload as “Transition.pdf”	<input type="checkbox"/>	
Partnership Statement – (<i>if applicable</i>) Attachment 13, upload as “Partnership.pdf”	<input type="checkbox"/>	
Representations (<i>Grants.gov submissions only</i>) – Attachment 14, upload as “RequiredReps.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Suggested Intragovernmental Budget Form (<i>if applicable</i>) – Attachment 15, upload as “IGBudget.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Additional Application Materials		
Research & Related Senior/Key Person Profile (Expanded)	<input type="checkbox"/>	<input type="checkbox"/>
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Budget	<input type="checkbox"/>	<input type="checkbox"/>
Project/Performance Site Location(s)	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Subaward Budget Attachment(s) (<i>if applicable</i>)	<input type="checkbox"/>	<input type="checkbox"/>

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Appendix 2. Acronym List

ACURO	Animal Care and Use Review Office
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
HIPAA	Health Insurance Portability and Accountability Act
IACUC	Institutional Animal Care and Use Committee
IPA	Impact Award
IRB	Institutional Review Board
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
OHRO	Office of Human Research Oversight (previously Human Research Protection Office)
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PPIO	Partnering PI Option
PRCRP	Peer Reviewed Cancer Research Program
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
UEI	Unique Entity Identifier

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

URL Uniform Resource Locator
USC United States Code
VA U.S. Department of Veterans Affairs